CA SB838

Requires the California Health and Human Services Agency (CHHSA) to establish metrics to measure progress and efficiency for drug manufacturing partnerships, with remedies if metrics are not met, and include these in partnership contracts.

Eliminates the requirement that insulin manufacturing pathways be "viable" and mandates partnerships consider guaranteeing priority access to insulin supply for the state.

Requires CHHSA to produce or distribute at least one form of insulin at production and dispensing costs, without requiring proof of market viability.

Authorizes CHHSA to enter into exclusive or nonexclusive contracts on a bid or negotiated basis until December 31, 2027, exempt from specified state procurement and contracting requirements.

Upon legislative appropriation, requires CHHSA to develop a California-based insulin manufacturing facility intended to create high-skill, high-paying jobs within the state.